Sionna Therapeutics, Inc. - Common Stock (NQ:SION)

4.910 -0.190 (-3.73%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sionna Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION

September 29, 2026

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION

September 22, 2026

From Pomerantz LLP

Via GlobeNewswire

Is This Biotech Stock Too Cheap to Ignore After Its Latest Pullback? ↗

September 18, 2026

This company has had plenty of setbacks in recent years, but it generally bounces back.

Via The Motley Fool

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION

September 15, 2026

From Pomerantz LLP

Via GlobeNewswire

Sionna Therapeutics Announces Plans to Advance SION-451 + SION-2222 Dual Combination into Phase 2a Proof-of-Concept Trial

September 14, 2026

From Sionna Therapeutics, Inc.

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION

September 08, 2026

From Pomerantz LLP

Via GlobeNewswire

Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now? ↗

September 04, 2026

They could both outperform the market over the medium term, but one appears to have a clear edge.

Via The Motley Fool

Topics Intellectual Property

SIONNA THERAPEUTICS INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Sionna Therapeutics Inc on Behalf of Sionna Therapeutics Stockholders and Encourages Investors to Contact the Firm

September 02, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION

September 01, 2026

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION

August 25, 2026

From Pomerantz LLP

Via GlobeNewswire

Vertex Pharmaceuticals' Rally Has a New Engine -- and Wall Street Thinks the Best Is Still Ahead ↗

August 20, 2026

Don't bet against Vertex Pharmaceuticals in cystic fibrosis.

Via The Motley Fool

Investigation Launched into Sionna Therapeutics, Inc. (SION), Robbins Geller Rudman & Dowd LLP Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm

August 19, 2026

From Robbins Geller Rudman & Dowd LLP

Via Business Wire

Securities Fraud Investigation Into Sionna Therapeutics, Inc. (SION) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

August 18, 2026

From Glancy Prongay Wolke & Rotter LLP

Via Business Wire

Sionna Therapeutics, Inc. (SION) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

August 18, 2026

From Law Offices of Howard G. Smith

Via Business Wire

Securities Fraud Investigation Into Sionna Therapeutics, Inc. (SION) Announced – Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz

August 17, 2026

From The Law Offices of Frank R. Cruz

Via Business Wire

Robbins LLP is Investigating the Recent Stock Drop of Sionna Therapeutics; Contact the Firm for Information

August 17, 2026

From Robbins LLP

Via Business Wire

SION Investors Have Opportunity to Join Sionna Therapeutics, Inc. Fraud Investigation with SBS Law

August 16, 2026

From Schall, Brown & Schwartz LLP

Via Business Wire

Vertex Pharmaceuticals Just Hit an All-Time High. Here's Why the Biotech Stock Could Soar Even More ↗

August 14, 2026

The drugmaker should significantly mitigate its most important risk as it develops new products.

Via The Motley Fool

SION Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Sionna Therapeutics (SION)

August 14, 2026

From Levi & Korsinsky, LLP

Via Business Wire

These stocks have an unusual volume in today's session ↗

August 13, 2026

Via Chartmill

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

August 12, 2026

Gainers BioVie (NASDAQ:BIVI) shares increased by 39.4% to $1.77 during Wednesday's regular session. The market value of their outstanding shares is at $9.5 million. Sionna Therapeutics (NASDAQ:SION)...

Via Benzinga

Sionna Halts SION-719 After Phase 2a Miss, Eyes SION-451 Combination Path ↗

August 11, 2026

Sionna Therapeutics (NASDAQ:SION) said its PreciSION CF Phase 2a proof-of-concept study of SION-719 added to Trikafta did not meet its key activity endpoint, prompting the company to discontinue...

Via MarketBeat

Sionna Therapeutics Reports Topline Data from Two Development Programs in Cystic Fibrosis and Provides Corporate Update

August 10, 2026

From Sionna Therapeutics, Inc.

Via GlobeNewswire

Could 1 Tiny Biotech Topple Vertex Pharmaceuticals' Cystic Fibrosis Empire? ↗

August 07, 2026

This risk is weighing on the stock.

Via The Motley Fool

Sionna Therapeutics Reports Second Quarter 2026 Financial Results

August 06, 2026

From Sionna Therapeutics, Inc.

Via GlobeNewswire

Sionna Therapeutics to Participate in Upcoming June 2026 Investor Conferences

May 27, 2026

From Sionna Therapeutics, Inc.

Via GlobeNewswire

Sionna Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

May 13, 2026

From Sionna Therapeutics, Inc.

Via GlobeNewswire

Sionna Therapeutics Reports First Quarter 2026 Financial Results

May 12, 2026

From Sionna Therapeutics, Inc.

Via GlobeNewswire

Sionna Insider Sells $2.5 Million in Stock Amid 215% Surge, but Here's What Investors Should Watch ↗

April 27, 2026

This biotech innovator in cystic fibrosis therapies reported a notable insider sale amid a year of standout stock performance.

Via The Motley Fool

Topics Regulatory Compliance

Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis

April 27, 2026

Topline data is on track for anticipated readout in the summer of 2026

From Sionna Therapeutics, Inc.

Via GlobeNewswire

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.